CGBio Co., Ltd., a company specializing in the research and manufacturing of implantable medical devices, said on the 26th it posted a consolidated operating profit of $2.6 million in 2025, turning to profit from an operating loss of $0.7 million a year earlier.
Over the same period, consolidated revenue rose 36% to $317 million from $232 million a year earlier, while net profit came to $44 million, reversing from a net loss the previous year, indicating a clear improvement in its overall earnings structure.
Consolidated revenue expanded as it reflected standalone revenue of $202 million along with contributions from its U.S. subsidiary and other affiliates.
The improvement in consolidated results was driven by a combination of standalone revenue growth, improved performance at its U.S. subsidiary, and the inclusion of dental business revenue following the addition of new subsidiaries.
Standalone performance also showed strong growth. Standalone revenue for 2025 increased 33% to $202 million from $152 million a year earlier, while operating profit rose 74% to $2.7 million. Net profit reached $57 million, turning to profit from a net loss the previous year.
In particular, the bone substitute business led overall growth. Revenue from bone substitutes increased nearly threefold from $17 million to $51 million, marking the highest growth rate, while spine product revenue rose from $9 million to $16 million, maintaining steady growth.
Domestic revenue in Asia surged from $43 million to $82 million. The company said enhanced sales execution, driven by the outsourcing and systemization of specialized marketing functions, along with the launch of its new spine product “INNOVERSE” and a bundled sales strategy tied to an expanded bone substitute portfolio, contributed to the gains.
Its overseas business also improved. U.S. revenue increased from $24 million to $30 million, while revenue at its U.S. subsidiary rose from $33 million to $41 million. Over the same period, operating loss narrowed from $11 million to $6 million, significantly improving profitability.
CEO Yoo Hyun-seung said, “In 2025, our growth drivers became clearly defined around the bone substitute and dental businesses, and our profit structure stabilized,” adding, “We will continue to strengthen both profitability and growth by expanding the share of high-value-added products and accelerating our push into global markets.”
